TOKYO – May 24, 2024 – Covidien Japan, Inc., (Head Office: Minato-ku, Tokyo), one of three Medtronic subsidiaries in Japan, concluded a service agreement on May 1 with HOGY Medical Co., Ltd. (Head Office: Minato-ku, Tokyo) to cooperate on the sale of SuReFInD®, a marking medical device used on lung cancer patients.

东京–2024年5月24日–美敦力在日本的三家子公司之一，Covidien Japan，Inc.（总部：东京Minato ku）于5月1日与HOGY Medical Co.，Ltd.（总部：东京Minato ku）签订了服务协议，合作销售SuReFInD®，SuReFInD®是一种用于肺癌患者的标志性医疗器械。

HOGY Medical is a marketing authorization holder for the product. The sale cooperation activities will commence successively from June. HOGY Medical’s SuReFInD®, which is used to mark lesions, fulfills the need for precise sub-lobar resection surgeries to treat lung cancer in its early stages, when legions can only be identified with diagnostic imaging equipment.

HOGY Medical是该产品的营销授权持有人。销售合作活动将从6月开始陆续开始。HOGY Medical的SuReFInD®用于标记病变，满足了在早期阶段进行精确的肺叶下切除手术以治疗肺癌的需要，当时只有通过诊断成像设备才能识别军团。

The aim is to combine this method with Endo GIA™️, Medtronic Covidien’s surgical stapler for lesion resection, in order to provide a comprehensive solution..

目的是将这种方法与Endo GIA™结合起来️, 美敦力Covidien的手术吻合器用于病变切除，以提供全面的解决方案。。

(Product name: SuReFInD/Approval number: 23000BZX00393000)

（产品名称：SuReFInD/批准号：23000BZX00393000）

There is a growing incidence of lung cancer not only in Japan but also worldwide. Moreover, as the nature of cancer is such that its risk increases with age, the number of patients is expected to increase further over the next 20 years in Japan, where there is a rising population of elderly people.

肺癌的发病率不仅在日本而且在世界范围内都在增长。此外，由于癌症的性质使得其风险随着年龄的增长而增加，因此在日本，老年人口不断增加，预计未来20年患者人数将进一步增加。

When lung cancer is discovered at an advanced stage, the typical surgical procedure performed is to excise extensive sections where lesions have developed, by the sac (lobe) unit. However, this is accompanied by the postoperative challenge of a decline in respiratory functions caused by the significant lung loss.

当晚期发现肺癌时，典型的外科手术是通过囊（叶）单位切除病变发展的广泛切片。然而，这伴随着由显着的肺损失引起的呼吸功能下降的术后挑战。

On the other hand, alongside advancements in CT and diagnostic imaging equipment in recent years, there has been an increase in the number of small-cell lung cancers detected, including early-stage microinvasive cancers with low malignancy. Therefore, early detection has been accompanied by a yearly increase in the number of limited resection surgeries for lung cancers without lymph node metastasis, aimed at reducing the resection area while preserving healthy lungs..

另一方面，随着近年来CT和诊断成像设备的进步，检测到的小细胞肺癌数量有所增加，包括恶性程度较低的早期微侵袭性癌症。因此，早期发现伴随着无淋巴结转移的肺癌有限切除手术数量的逐年增加，旨在减少切除面积，同时保持健康的肺部。。

The main methods adopted for resection surgeries include resecting the lung by using a surgical stapler such as Endo GIA™️. As it is possible to preserve lung functions by reducing the resection area, patients can be expected to maintain their quality of life after treatment and be rehabilitated into society more quickly..

切除手术采用的主要方法包括使用外科吻合器（如Endo-GIA™）切除肺部️. 由于可以通过减少切除面积来保持肺功能，因此可以期望患者在治疗后保持其生活质量，并更快地康复。。

However, unlike cancers that develop on the inner surface of the digestive tract, such as stomach cancer and colorectal cancer, which can be confirmed directly through an endoscopy, lung cancer cannot be observed directly during surgery. Furthermore, as the shape of the lung changes significantly between diagnostic imaging (when inflated after an intake of breath) and during surgery (when collapsed), it becomes challenging to identify and resect the lesion with precision during surgery.

然而，与消化道内表面发生的癌症（如胃癌和结直肠癌）不同，可以通过内窥镜检查直接确诊，肺癌不能在手术过程中直接观察到。此外，由于肺的形状在诊断成像（吸气后充气）和手术期间（塌陷时）之间发生显着变化，因此在手术期间精确识别和切除病变变得具有挑战性。

Even with limited resection surgeries that involve a small resection area, it is vital to ensure that there is an adequate resection margin (distance) from the lesion so that cancerous tissue is not left behind..

即使是涉及小切除区域的有限切除手术，也必须确保与病变有足够的切除边缘（距离），以便不留下癌组织。。

To resolve these issues, SuReFInD® is used to carry out marking procedures and embed an IC tag in or near the lung cancer lesion before surgery. By using SuReFInD®, an in-vivo medical device that employs RFID technology, it is possible to check the location of the lesion more accurately and in real-time during surgery through the RFID communications technology.

为了解决这些问题，SuReFInD®用于执行标记程序，并在手术前将IC标签嵌入肺癌病变内或附近。通过使用SuReFInD®（一种采用RFID技术的体内医疗设备），可以通过RFID通信技术在手术过程中更准确和实时地检查病变的位置。

Combining this with lesion resection using Endo GIA™️ enables the provision of a comprehensive solution that meets the needs of precise sub-lobar resection surgeries..

结合使用Endo-GIA™进行病变切除️ 能够提供全面的解决方案，满足精确的肺叶下切除手术的需要。。

With the conclusion of this service agreement between Covidien Japan and HOGY Medical, as well as the establishment of a system to supply and sell a comprehensive solution that combines SuReFInD® and Endo GIA™️, the two companies aim to promote the widespread adoption of precise sub-lobar resection surgery on lungs, reduce patients’ burden in receiving treatment, and contribute to improving prognosis after the surgery..

随着Covidien Japan和HOGY Medical签订本服务协议，以及建立一个系统来提供和销售结合SuReFInD®和Endo GIA™的综合解决方案️, 两家公司的目标是促进肺部精确肺叶下切除手术的广泛采用，减轻患者接受治疗的负担，并有助于改善手术后的预后。。

■ Comments from Dr. Toshihiko Sato, Professor, Department of Surgery (Thoracic, Endocrine, Pediatric), Fukuoka University Hospital

■ 福冈大学医院外科（胸腔、内分泌、儿科）教授佐藤俊彦博士的评论

As thoracic surgeons, we aim to improve the treatment outcomes for lung cancer and reduce mortality from lung cancer by promoting and developing precise sub-lobar resection (PSR) surgery for the lungs. I believe that the technology built into SuReFInD® is necessary for performing such PSR, and I think that it can be one of the more effective treatment options for small-cell lung cancer..

作为胸外科医生，我们的目标是通过促进和发展精确的肺叶下切除术（PSR）手术来改善肺癌的治疗效果并降低肺癌的死亡率。我相信SuReFInD®内置的技术对于执行此类PSR是必要的，我认为它可能是小细胞肺癌更有效的治疗选择之一。。

■ Comments from Keizo Kumano, Vice President, Medical Surgical Unit, Medtronic Japan

■ 美敦力日本医疗外科副总裁熊野惠三的评论

We have set out the vision of continuing to be a leading partner in developing surgical procedures and strengthening outcomes through our innovative solutions. The number of lung cancer patients is expected to increase going forward as we approach the era of a super-aging society. In light of that, Medtronic will take a multifaceted approach that smoothly links diagnosis to appropriate treatment, with the aim of improving patients’ prognosis and realizing a society where they can lead healthy lives..

我们提出了继续成为开发外科手术和通过创新解决方案加强成果的领先合作伙伴的愿景。随着我们接近超老龄化社会的时代，肺癌患者的数量预计会增加。有鉴于此，美敦力将采取多方面的方法，将诊断与适当的治疗顺利联系起来，旨在改善患者的预后，实现一个他们可以健康生活的社会。。

■ Comments from Hideki Kawakubo, Director, President and CEO, HOGY Medical

■ HOGY Medical董事、总裁兼首席执行官Hideki Kawakubo的评论

As the aging of society picks up speed, advancements have been made in minimally invasive treatments and surgeries that reduce the burden on patients’ bodies. The sales cooperation with Covidien will enable the provision of SuReFInD® to even more patients. Through that, we aim to realize medical services of an even higher quality, and to do our best to achieve health and well-being for patients..

随着社会老龄化速度的加快，微创治疗和手术取得了进步，减轻了患者身体的负担。与Covidien的销售合作将为更多患者提供SuReFInD®。通过这一点，我们的目标是实现更高质量的医疗服务，并尽最大努力为患者实现健康和福祉。。

[About SuReFInD®]

[关于SuReFInD®]

SuReFInD® is a marking medical device, developed for the purpose of supporting more accurate resection in lung resection surgeries to treat small-cell lung cancers. It was launched for sale in 2020. A microscopic IC tag that applies RFID technology is placed near the lesion via the bronchoscope channel.

SuReFInD®是一种标志性医疗设备，旨在支持肺切除手术中更准确的切除，以治疗小细胞肺癌。它于2020年推出销售。应用RFID技术的显微IC标签通过支气管镜通道放置在病变附近。

During the surgery, a specialized small antenna is used to accurately determine the location of the lesion for the resection..

在手术过程中，使用专门的小天线来准确确定切除病变的位置。。

[About marking medical devices]

[关于标记医疗器械]

These are devices used to mark the resection area on surgical sites where it is difficult to identify the location of tumors during a surgery. They are mainly used in surgeries involving lung cancer, stomach cancer, and colorectal cancer.

这些设备用于标记手术部位的切除区域，在手术过程中难以识别肿瘤的位置。它们主要用于涉及肺癌，胃癌和结直肠癌的手术。

[About RFID technology]

[关于RFID技术]

Radio frequency identification (RFID) technology is an automatic recognition technology that uses radio frequencies to read and write information on IC tags without any contact.

射频识别（RFID）技术是一种自动识别技术，它使用射频在不需要任何接触的情况下读取和写入IC标签上的信息。

[About Endo GIA™️]

[关于Endo GIA™️]

Endo GIA™️ is an automatic suturing device (a type of surgical stapler) developed specially for use in endoscopic surgery, and it was the first of its kind sold in the world when it was launched in 1992. It is used primarily in resection, transection, and anastomosis (connecting the intestinal tracts and other structures in surgery).

Endo GIA™️ 是一种专门为内窥镜手术开发的自动缝合装置（一种外科吻合器），1992年推出时是世界上第一款此类缝合装置。它主要用于切除，横断和吻合（在手术中连接肠道和其他结构）。

As a suturing method to replace surgical stitching alongside the popularization of minimally invasive surgeries such as endoscopic surgeries, Endo GIA™️ has a history of contributing to reducing surgery time and evolving continuously. In lung surgeries, it is used for the resection and transection of lesions.

作为替代外科缝合的缝合方法，随着微创手术（如内镜手术）的普及，Endo GIA™️ 有助于减少手术时间并不断发展的历史。在肺部手术中，它用于切除和横切病变。

By gripping the tissue and operating the handle, the mechanism enables the stapler and resecting knife to operate at the same time, thereby performing the suturing and resecting functions simultaneously. Furthermore, it comes with an extensive range of suture lengths of 30mm, 45mm, and 60mm, in addition to a diverse variety of cartridges.

通过抓住组织并操作手柄，该机构使吻合器和切除刀同时操作，从而同时执行缝合和切除功能。此外，除了各种各样的墨盒之外，它还具有30mm，45mm和60mm的广泛缝合长度。

This supports transection in line with the surgical plan in precise sub-lobar surgeries..

这支持根据精确的肺叶下手术的手术计划进行横切。。

Product name: Endo GIA/Approval number: 22100BZX00167000

产品名称：Endo GIA/批准号：22100BZX00167000

Product name: Tri-Staple 2.0/Approval number: 22900BZX00115000

产品名称：Tri-Staple 2.0/批准号：22900BZX00115000

Product name: Signia Small Diameter Reload/Approval number: 30200BZX00023000

产品名称：Signia小直径重新装载/批准号：30200BZX00023000

Product name: Tri-Staple 2.0 Reinforced Reload/Approval number: 30300BZX00229000

产品名称：Tri-Staple 2.0钢筋重新加载/批准号：30300BZX00229000

Product name: Endo GIA Ultra Universal Stapler/ Certification number: 223AABZX00019000

产品名称：Endo GIA Ultra Universal订书机/认证号：223AABZX00019000

Product name: Signia Stapling System/Certification number: 228AABZX00088Z00

产品名称：Signia装订系统/认证号：228AABZX00088Z00

Product name: Signia Manual Adapter Tool/Notification number: 13B1X00069US023A

产品名称：Signia手动适配器工具/通知编号：13B1X00069US023A

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆的行动。我们是美敦力。总部位于爱尔兰都柏林的美敦力公司（Medtronic plc）是全球领先的医疗保健技术公司，通过寻找和寻找解决方案，大胆应对人类面临的最具挑战性的健康问题。我们的使命是减轻痛苦，恢复健康，延长生命，我们将150多个国家的95000多名充满激情的全球团队团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们丰富的知识、永不满足的好奇心以及帮助所有需要帮助的人的愿望，我们提供了创新技术，每秒钟、每小时、每天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn..

随着我们增强洞察力驱动的护理、以人为本的体验以及为我们的世界带来更好的结果，对我们的期望会更高。在我们所做的每件事中，我们都在创造非凡。有关美敦力的更多信息，请访问www.Medtronic.com，并在LinkedIn上关注美敦力。。

About HOGY Medical

关于HOW Medical

HOGY Medical Co., Ltd. has been engaged in the development of products that contribute to enhancing medical safety and improving profits for medical institutions since its establishment in 1961, based on the corporate philosophy of 'To promote good health and prosperity through contribution to medical progress.” Its history began with sterilization pouches, which it started selling in 1964 with the aim of preventing hospital-acquired infections.

霍吉医疗有限公司自1961年成立以来，一直致力于开发有助于提高医疗安全和提高医疗机构利润的产品，其企业理念是“通过对医疗进步的贡献促进健康和繁荣”它的历史始于消毒袋，1964年开始销售，目的是防止医院感染。

Since then, it has strived to ensure the stable supply of products that are safe and easy to use, including medical-use non-woven fabric products and surgical kit products. It also provides the OPERA MASTER, a system that contributes to improving management at medical institutions, as well as the Premium Surgical Kit in 2016 to support medical practitioners who are engaged in work style reform.

从那时起，它一直努力确保安全易用的产品的稳定供应，包括医疗用无纺布产品和手术套件产品。它还提供OPERA MASTER，这是一个有助于改善医疗机构管理的系统，以及2016年的优质手术包，以支持从事工作方式改革的医生。

By working with doctors on the joint development of products that contribute to improving the quality of medical services, among other efforts, it continues to evolve with future advancements in minimally invasive treatment, which aims to reduce the burden on patients' bodies..

通过与医生合作，共同开发有助于提高医疗服务质量的产品，以及其他努力，它将随着微创治疗的未来进步而不断发展，旨在减轻患者身体的负担。。